Search

Steingrimur Stefansson Phones & Addresses

  • 46430 Peary Ct, Novi, MI 48377
  • 5 Boxberry Ct, Gaithersburg, MD 20879 (301) 926-4855
  • Derwood, MD
  • East Setauket, NY
  • North Chesterfield, VA
  • 5 Boxberry Ct, Gaithersburg, MD 20879

Work

Company: Molecular innovations Nov 2017 Position: Senior scientist

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Virginia Commonwealth University 1986 to 1990 Specialities: Molecular Biology, Biochemistry, Philosophy

Skills

Elisa • Cell Culture • Protein Expression • Fluorescence Microscopy • Antibodies • Tissue Culture • Immunoassays • Animal Models • Immunohistochemistry • Gel Electrophoresis • Protein Engineering • Protein Structure • Fda • Protein Assays • Protein Analysis • Circulating Tumor Cells • Mammalian Cell Culture • Blood • Enzyme Assays • Cancer Research • Grant Writing • Protein Production • Protein Folding • Protein Protein Interactions • Protein Modification • Proteinases • Proteinase Inhibitors • Sequence Analysis • Filtration • Carbon Nanotubes • Protein Preservation • Enzyme Activity • Angiogenesis • Cell Adhesion • Cell Migration • Platelets • Neutrophils • Monoclonal Antibodies • Immunofluorescence • Immunoprecipitation • Immunostaining • Column Chromatography • Manuscript Writing • Integrin • Mmp • Serine Proteinases • Proteases • Virus Culture • Bacterial Culture • Bacterial Transformation

Languages

Icelandic • English • Danish • German

Interests

Children • Civil Rights and Social Action • Education • Environment • Disaster and Humanitarian Relief • Arts and Culture • Health

Industries

Biotechnology

Resumes

Resumes

Steingrimur Stefansson Photo 1

Senior Scientist

View page
Location:
Gaithersburg, MD
Industry:
Biotechnology
Work:
Molecular Innovations
Senior Scientist

Fuzbien May 2010 - Feb 2014
Director Assay Development

Hememics Biotechnologies, Inc May 2010 - Feb 2014
Director of R and D

Creatv Microtech, Inc. 2007 - May 2010
Senior Scientist

University of Maryland School of Medicine 2004 - Nov 2007
Assistant Professor
Education:
Virginia Commonwealth University 1986 - 1990
Doctorates, Doctor of Philosophy, Molecular Biology, Biochemistry, Philosophy
Háskóli Íslands 1981 - 1984
Bachelors, Bachelor of Science, Biology, Organic Chemistry
Skills:
Elisa
Cell Culture
Protein Expression
Fluorescence Microscopy
Antibodies
Tissue Culture
Immunoassays
Animal Models
Immunohistochemistry
Gel Electrophoresis
Protein Engineering
Protein Structure
Fda
Protein Assays
Protein Analysis
Circulating Tumor Cells
Mammalian Cell Culture
Blood
Enzyme Assays
Cancer Research
Grant Writing
Protein Production
Protein Folding
Protein Protein Interactions
Protein Modification
Proteinases
Proteinase Inhibitors
Sequence Analysis
Filtration
Carbon Nanotubes
Protein Preservation
Enzyme Activity
Angiogenesis
Cell Adhesion
Cell Migration
Platelets
Neutrophils
Monoclonal Antibodies
Immunofluorescence
Immunoprecipitation
Immunostaining
Column Chromatography
Manuscript Writing
Integrin
Mmp
Serine Proteinases
Proteases
Virus Culture
Bacterial Culture
Bacterial Transformation
Interests:
Children
Civil Rights and Social Action
Education
Environment
Disaster and Humanitarian Relief
Arts and Culture
Health
Languages:
Icelandic
English
Danish
German

Business Records

Name / Title
Company / Classification
Phones & Addresses
Steingrimur Stefansson
Director
Fuzbien Technology Institute, Inc
Rnd Engineering Srvcs
9700 Great Seneca Hwy, Rockville, MD 20850
(301) 602-4014, (240) 386-8040

Publications

Us Patents

Induction Of Blood Vessel Formation Through Administration Of Polynucleotides Encoding Sphingosine Kinases

View page
US Patent:
6610534, Aug 26, 2003
Filed:
Oct 4, 2001
Appl. No.:
09/970516
Inventors:
Gene Liau - Darnestown MD
Steingrimur Stefansson - Gaithersburg MD
Joseph Su - Germantown MD
Assignee:
Novartis AG - Basel
International Classification:
C12N 1563
US Classification:
4353201, 4352523, 514 44, 536 231, 536 235, 536 234
Abstract:
A method of inducing blood vessel formation in an animal by administering to the animal a polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof. The polynucleotide may be contained in an appropriate expression vector, such as a viral vector. The delivery of sphingosine kinase through administration of an expression vector which expresses sphingosine kinase provides for the formation of larger blood vessels containing a well defined structure that is supported by mural cells such as pericytes and smooth muscle cells.

Methods And Compositions For Hdl Holoparticle Uptake Receptor

View page
US Patent:
6846636, Jan 25, 2005
Filed:
May 13, 1999
Appl. No.:
09/700455
Inventors:
William S. Argraves - Charleston SC, US
Samar Hammad - Charleston SC, US
Steingrimur Stefansson - Gaithersburg MD, US
Bryan Brewer - North Bethesda MD, US
Alan Remaley - Bethesda MD, US
Assignee:
American National Red Cross - Falls Church VA
The United States of America as represented by the Department of Health and Human Services - Washington DC
MUSC Foundation for Research Development - Charleston SC
International Classification:
G01N 3353
G01N 33566
G01N 3392
C12Q 162
C07K 1400
US Classification:
435 71, 435 11, 436501, 436 71, 530350
Abstract:
The present invention provides an isolated mammalian receptor which specifically binds a high density lipoprotein holoparticle, comprising a subunit of approximately 45-600 kDa molecular weight and one or more subunits selected from the group consisting of a subunit of approximately 40-50 kDa molecular weight, a subunit of approximately 120 kDa molecular weight and a subunit of approximately 400 kDa molecular weight. In addition, the present invention provides a method of screening a substance for the ability to modulate the HDL holoparticle binding and/or internalization activity of the receptor of this invention, comprising: a) contacting the substance with a cell producing a functional HDL receptor; and b) assaying the cell for a modulation of the HDL holoparticle binding and/or internalization activity of the receptor, whereby a modulation of the HDL holoparticle binding and/or internalization activity of the receptor identifies a substance with the ability to modulate the HDL holoparticle binding and/or internalization activity of the ADL receptor.

Induction Of Blood Vessel Formation Through Administration Of Polynucleotides Encoding Sphingosine Kinases

View page
US Patent:
20040086487, May 6, 2004
Filed:
Jul 14, 2003
Appl. No.:
10/619344
Inventors:
Gene Liau - Darnestown MD, US
Steingrimur Stefansson - Gaithersburg MD, US
Joseph Su - Germantown MD, US
Assignee:
Novartis AG
International Classification:
A61K048/00
US Classification:
424/093200, 435/456000, 424/094500
Abstract:
A method of inducing blood vessel formation in an animal by administering to the animal a polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof. The polynucleotide may be contained in an appropriate expression vector, such as a viral vector. The delivery of sphingosine kinase through administration of an expression vector which expresses sphingosine kinase provides for the formation of larger blood vessels containing a well defined structure that is supported by mural cells such as pericytes and smooth muscle cells.

Endothelial Cell Specifically Binding Peptides

View page
US Patent:
20060223756, Oct 5, 2006
Filed:
Dec 17, 2003
Appl. No.:
10/537847
Inventors:
Gene Liau - Wayland MA, US
Steingrimur Stefansson - Gaithersburg MD, US
Joseph Su - Germantown MD, US
International Classification:
A61K 38/10
A61K 38/08
C07K 7/08
C07H 21/04
C12P 21/04
US Classification:
514016000, 435069700, 435456000, 435325000, 514017000, 530328000, 530329000, 530330000, 536023500
Abstract:
The present invention relates to peptides that specifically bind to endothelial cells. The peptides can be incorporated into gene delivery vector particles and can also direct therapeutic agents, including proteins such as growth factors and cytokines as well as small molecules. The vector particles, peptides, or small molecules can be used for the treatment of cancer and cardiovascular diseases such as ischemic heart disease, peripheral limb disease, vein graft stenosis and restenosis.

Sample Preparation And Detection Of Analytes Using Silica Beads

View page
US Patent:
20110039267, Feb 17, 2011
Filed:
Aug 13, 2010
Appl. No.:
12/856448
Inventors:
Cha-Mei Tang - Potomac MD, US
Daniel Adams - Kensington MD, US
Steingrimur Stefansson - Gaithersburg MD, US
International Classification:
C12Q 1/68
G01N 33/569
B01D 15/04
US Classification:
435 6, 435 737, 210660, 210263
Abstract:
This invention provides methods for concentration of analyte from biological sample, or various liquid samples and methods for identification of the analyte. The method includes providing silica beads conjugated with analyte recognition element for concentration of analyte from sample, packaging the beads into a cartridge, and attaching the cartridge to a sample holder. After the analyte concentration, additional steps can be implemented to identify the analyte to provide visual positive/negative, qualitative or quantitative results. Another exemplary embodiment of the present invention provides a system for concentration of analyte from biological sample or other various liquid samples using silica beads. According to an exemplary implementation, the system includes a cartridge comprising silica beads conjugated with analyte recognition element to concentrate at least one analyte from the sample, and a sample holder having the cartridge attached thereto. A sample is passed through the cartridge.

Mutant Plasminogen Activator-Inhibitor Type 1 (Pai-1) And Uses Thereof

View page
US Patent:
61034983, Aug 15, 2000
Filed:
Apr 11, 1997
Appl. No.:
8/840204
Inventors:
Daniel A. Lawrence - Derwood MD
Steingrimur P. Stefansson - Gaithersburg MD
Assignee:
American National Red Cross - Washington DC
International Classification:
C12P 2106
C12N 966
C07K 100
C07H 2104
US Classification:
435 692
Abstract:
Mutants of the human PAI-1 protein are described which are inhibitors of neutrophil elastase or are inhibitors of vitronectin (Vn)-dependent cell migration. These mutants preferably comprise one or two amino acid substitutions in the reactive center loop of PAI-1, particularly at positions 331 and 346 of the mature protein. These mutants are notable in being resistant to inactivation by elastase, having high affinity for Vn, or both properties. These mutant proteins as pharmaceutical compositions are used to inhibit elastase in a subject, thereby treating a number of disorders associated with elastase activity, most notably emphysema, ARDS, inflammatory lung injury and cystic fibrosis. The mutants which interact with Vn are used to inhibit cell migration in a subject, thereby treating diseases or conditions associated with undesired cell migration and proliferation, particularly of smooth muscle cells. Such conditions include atherosclerosis, post angioplasty restenosis, fibrosis associated with chronic inflammation or chemotherapy, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic.
Steingrimur P Stefansson from Novi, MI, age ~64 Get Report